Connect with us
  • Elysium


Daily News Round Up: Monday, 11 March



Daily News Round Up: Monday, 11 March

Welcome to your daily round-up of everything happening in the world of neurorehabilitation.

Research news

University-wide alliance to address multiple disease areas

Harvard University and Ono Pharmaceutical have launched a strategic alliance to advance research across a broad range of therapeutic areas. This collaborative effort marks a significant commitment to identify and develop first-in-class therapeutics for medical conditions in the areas of oncology, immunology, neurology, and specialty.

Polyglots process native language with ease

In the brains of people who speak five or more languages, the same language regions light up when they listen to any of the languages that they speak. In general, this network responds more strongly to languages in which the speaker is more proficient, with one notable exception: the speaker’s native language. When listening to one’s native language, language network activity drops off significantly. The findings suggest there is something unique about the first language one acquires, which allows the brain to process it with minimal effort.

Deciphering the tip of migrating neurons

A new study has found that migrating neurons possess a growth cone that shares functions with axonal growth cones and regulates neuronal migration by interaction with the extracellular environment. A research group led by Kazunobu Sawamoto, Professor at Nagoya City University and National Institute for Physiological Sciences, and by Chikako Nakajima and Masato Sawada, staff scientists in his laboratory, has found that the PTPσ-expressing growth cone senses the extracellular matrix and drives neuronal migration in the injured brain, leading to functional recovery.

Company and financial neuro-rehab news

KYV-101 for Non-Relapsing and Progressive Forms of Multiple Sclerosis

Kyverna Therapeutics, a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, has announced the signature of a collaboration agreement with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label, phase 1 investigator-initiated trial (IIT) in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis.

Allen Institute joins the Weill Neurohub

The Allen Institute has officially become the newest member of the Weill Neurohub, a collaborative research network advancing treatments for neurological diseases. The new partnership will integrate the Allen Institute’s expertise in large-scale brain mapping and brain recording with the cutting-edge research of the Weill Neurohub’s founding members: the University of California, Berkeley; the University of California, San Francisco; and the University of Washington.

Technology news

Protecting Cognition: Background Paper on Neurotechnology

The Australian Human Rights Commission has published a paper – Protecting Cognition: Background Paper on Neurotechnology and Human Rights. The background paper was informed by qualitative consultations with 47 participants, while a further 22 participants provided written feedback. Participants represented civil society, academia, regulators, law, industry and government, and represents an important first step in stimulating discussions and identifying gaps in the Australian response to neurotechnologies.